



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Journal Pre-proof

Stroke Risk Related to COVID-19: What Have We Learned?

Pamela Pourciau, MSN, NP-C, SCRN, NC-BC, Britta C. Smith, DNP, FNP



PII: S0899-5885(22)00096-X

DOI: <https://doi.org/10.1016/j.cnc.2022.10.001>

Reference: CNC 1068

To appear in: *CRITICAL CARE NURSING CLINICS OF NORTH AMERICA*

Please cite this article as: Pourciau P, Smith BC, Stroke Risk Related to COVID-19: What Have We Learned?, *CRITICAL CARE NURSING CLINICS OF NORTH AMERICA* (2022), doi: <https://doi.org/10.1016/j.cnc.2022.10.001>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier Inc.

Stroke Risk Related to COVID-19: What Have We Learned?

Pamela Pourciau, MSN, NP-C, SCRNP, NC-BC

East Jefferson Neurological Associates

236 Dunleith Drive Destrehan, Louisiana 70047

pamela.pourciau@lcmchealth.org

Corresponding Author

Britta C. Smith, DNP, FNP

East Jefferson General Hospital

4200 Houma Boulevard

Metairie, Louisiana 70006

britta.smith@lcmchealth.org

KEY WORDS

- Ischemic stroke ● Risk ● COVID-19 ● SARS-CoV-2

KEY POINTS

- COVID-19 and stroke risk
- Stroke risk in SARS-CoV-2
- Ischemic stroke in patients with COVID-19

INTRODUCTION

Since its initial outbreak in December 2019, the novel SARS-CoV-2 (COVID-19) virus with its associated severe acute respiratory disease and pneumonia began to spread worldwide.¹ Though COVID-19 is primarily associated with the pulmonary system, the virus can lead to damaging diseases that affect multiple organ systems including the central nervous system. Various neurological manifestations and disorders associated with COVID-19 can range from mild symptoms such as headache or myalgias to more severe disorders including Guillain-Barre' syndrome, seizures, and psychosis. Though some of these neurological associations are mild and likely reversible, significant numbers of patients with COVID-19 experience a stroke.¹

On March 11, 2020, the World Health Organization declared COVID-19 to be a pandemic and since then, reports of increased risk for acute ischemic stroke (AIS) in those with COVID-19 began to emerge and continues to evolve.²

DISCUSSION

Stroke care is based on the American Stroke Association Guidelines.^{3,4} Timely presentation to the nearest hospital reduces delay of care to potentially offer interventions such as intravenous thrombolytic or cerebral thrombectomy. Delay of care increases the likelihood of being ineligible for these interventions, thereby increasing mortality and morbidity related to stroke. The COVID-19 pandemic caused a tremendous strain on the healthcare system world-wide because of the lack of treatment methods for patients infected with COVID-19. It overburdened emergency rooms and overwhelmed medical staff which impacted stroke care. Patients with transient ischemic attacks or those with mild stroke symptoms refrained from presenting to the emergency room or declined admission out of fear.⁵

At the beginning of the pandemic, The World Health Organization had recommended the reduction of exposure with the use of protective personal equipment, social distancing, avoiding crowds, home confinement, and for healthcare systems to cease all nonessential services and elective surgeries to reduce the spread of the virus.⁶ Studies suggested that because of the isolation requirements, people with stroke symptoms either did not know they were experiencing a stroke or delayed seeking care thereby limiting interventions.⁵

RESEARCH

Early in the pandemic, COVID-19 began to become associated with acute ischemic stroke. Patients with the COVID-19 infection in China were noted with coagulopathy and antiphospholipid antibodies. They were elderly patients with severe infection prone to cerebrovascular events and younger patients, less than 50 years of age with large vessel strokes.⁷ A study in the United States confirmed a significant incident of acute stroke in patients with COVID-19 infection and found COVID-19 to be an independent risk factor for acute ischemic stroke. Therefore, patients with COVID-19, should have continuous monitoring for acute ischemic stroke.⁸

Reports of neurologic involvement in 30% to 50% of all individuals with SARS-CoV-2 infection have been defined, with almost half of these attributable to stroke.⁹ According to Mao and associates, early reports from Wuhan ascertained that more than 36% of patients with COVID-19 had some degree of neurologic involvement, most commonly affecting the central nervous system.¹⁰ Maury and colleagues found that up to 73% of hospitalized patients with COVID-19 experienced some type of neurological symptom.¹¹ These same authors also reported that acute cerebrovascular diseases, predominately acute ischemic stroke, have been found in 0.7 to 5.8% of hospitalized patients with COVID-19. The increased risk of ischemic stroke and intracranial hemorrhage with or post COVID-19 was evident in study after study. An alarming finding by Taquet and colleagues¹² showed that incidence of ischemic stroke was almost one in ten or (three in 100 for a first stroke) in patients with encephalopathy (n = 236, 379).

In one of the earliest studies, with data collected from January 16, 2020, to February 19, 2020, from three special care centers in Wuhan, China, Mao and

colleagues¹⁰ found that of the 214 patients, 36.4% or 78 patients had neurological sequelae. Severe infection, characterized by respiratory status, was seen in 88 patients (41.1%) and of those, 5.7% had acute cerebrovascular disease and 14.8% demonstrated impairment of consciousness. Those with severe infection were older and had more comorbidities, specifically hypertension.¹⁰

A review of eleven studies outlines the frequency that cerebrovascular disease is shown to correlate with COVID-19, with the focus being ischemic stroke

Table 1. Correlation of cerebrovascular disease with COVID-19

Study Methodology	Neurologic Manifestations	Total Number	Number of Strokes	Percent %	Authors
Retrospective Observational	Cerebrovascular Disease Ischemic Stroke – 5 Hemorrhagic Stroke – 1	214	6	2.8	Mao, et al. (2020) ¹⁰
Single center Retrospective, Observational	Cerebrovascular Disease Ischemic Stroke – 10 Hemorrhagic Stroke – 1	219	11	5	Li, Li, Wang, Zou, et al. (2020) ¹³
Multicenter, multinational, Observational, Systematic Review, Meta-Analysis	Strokes Ischemic Stroke - 123 Hemorrhagic Stroke - 27 Cerebral Venous Thrombosis - 6	17,779	156	0.9 (Pooled risk)	Shahjouei, Naderi, et al. (2020) ¹⁴
Systematic Review, Meta-Analysis	Ischemic Stroke	8,577	226	2.6	Huth, Cho, Robba, et al. (2021) ¹⁵
Multicenter, Retrospective	Ischemic Stroke	41,971	1143	2.7	Srivastava, Zhang, Xian et al. (2021) ¹⁶
Multicenter, Retrospective	Ischemic Stroke Hemorrhagic Stroke Cerebral Venous Thrombosis	725	34 6 2	4.7 0.8 0.3	Mahedmedi, et al. (2020) ¹⁷
Retrospective, Observational	Ischemic Stroke Hemorrhagic Stroke	841	11	1.3	Romero-Sanchez, Diaz-Maroto, et al. (2020) ¹⁸
Systematic Review, Meta-Analysis	Acute Cerebrovascular Disease Acute Ischemic Stroke – 1329 Intracerebral Hemorrhage – 180	108,571	1409	1.3	Nanooni, DeGroot, Bell, et al. (2021) ¹⁹
Retrospective Cohort	Acute Cerebrovascular Disease Acute Ischemic Stroke/TIA – 160 Intracerebral Hemorrhage – 44 Subarachnoid Hemorrhage – 33 Epidural/Subdural Hemorrhage -21 Central Venous Thromboses - 2	21,073	284	1.4 (Pooled risk)	Shakil, Emmons-Bell, Rutan, et al. (2022) ²⁰

	Not Otherwise Classified – 24				
Retrospective Cohort	Acute Ischemic Stroke	8,163	103	1.6	Qureshi, et al (2021) ²¹
Retrospective Observational Cohort	Ischemic Stroke	14,483	156	0.8	Siegler (2021) ²²

Roman and colleagues²³ found that central nervous system manifestations such as headache, partial or total loss of smell (hyposmia, anosmia) and distorted (dysgeusia), diminished (hypogeusia), or loss (ageusia) of taste perception to be common early symptoms of COVID-19 infection. In fact, changes in taste and smell sensation were often used as primary screening symptoms for COVID-19. Considering the anatomy of the olfactory nerve and cribriform plate, this might suggest how the virus gains access to the brain. Respiratory failure is often a main cause of death related to COVID-19 and this pathway may explain how the COVID-19 virus gains access to the rhinencephalon and brainstem centers.²³

Cerebrovascular disease, primarily large vessel ischemic strokes, and to a lesser degree cerebral venous thrombosis, intracerebral hemorrhage, and subarachnoid hemorrhage, are thought to occur as part of a thrombotic state generated by the virus attaching to ACE2 endothelial receptors leading to extensive endothelial inflammation, coagulopathy, as well as arterial and venous thromboses.²³

. Below is a table of common stroke features obtained from a variety of research studies primarily, from data procured in 2019 - early 2021.

Table 2. Features of Stroke in COVID-19

Common Findings Across Studies Reviewed	References
More Common in Younger Patients (mean < 55 years) without classic vascular risk factors	Shahjouei, Tsivgoulis, Farahmand ²⁴ (2021); Jabbour ²⁵ (2022); Zhang, Xiao ⁷ (2020)
More common among younger (ages 65–74 years) Medicare beneficiaries and among Medicare beneficiaries without prior history of stroke.	Yang, Tong, George (2022) ²⁶
Higher prevalence of cryptogenic stroke	Shahjouei, Tsivgoulis, Farahmand ²⁷ (2021); Yang, Tong, George ²⁶ (2022); Stein ²⁸ (2021); Siegler ²⁹ (2021)
Increased incidence of large vessel occlusion stroke	Lee, Khan, Ching ³⁰ (2020); John, Kesav, Mifsud ³¹ (2020); Shahjouei, Tsivgoulis, Farahmand ²⁷ (2021). Shahjouei, Anyaehie, Koza et al. ³² (2021); Roman, Spencer, & Reis ²³ (2020); Li, Wang, & Zou ¹³ (2020); Nanonni ¹⁹ (2021)
Smaller incidence of small vessel occlusion stroke and lacunar stroke	Shahjouei, Tsivgoulis, Farahmand (2021) ²⁷
Stroke more severe	Ntaios (2020); Siegler ³³ (2021)
Patients more critically ill, on mechanical ventilator, with ischemic heart disease	Li, Li, Wang, Zhou (2020) ¹⁰
Higher mortality (in-hospital)	Nanonni, de Groot, Bell ¹⁹ (2021); Quereshi ²¹ (2021); Siegler ²⁹ (2021)

Increased morbidity and mortality	Stein, Mayman, Dhamoon ²⁸ (2021); Ntaios ³³ (2020); Jabbour (2022)
Worse functional outcomes	Ntaios ³³ (2020)
Increased incidence of stroke with severe COVID-19	Mao, Jin, Wang ¹⁰ (2020); Nanonni, de Groot, Bell ¹⁹ (2021)
Increased incidence of multi-territory strokes	Nanonni, de Groot, Bell ¹⁹ (2021); Yang, Tong, George ²⁶ (2022)

Yang and colleagues ²⁶ in their systematic review and meta-analysis of Medicare beneficiaries 65 years and older, examined the characteristics and outcomes of patients with COVID-19 and stroke and found a pooled incidence of 1.4% of acute cerebrovascular disease. In their study, they found that most patients admitted with COVID-19 symptoms developed stroke a few days later. The strokes were usually ischemic in nature, cryptogenic in cause, and often distinguished by multiple cerebral infarctions.²⁶

When determining risk factors for stroke incidence in patients with COVID-19, Nannoni and associates ¹⁹ examined four studies. These researchers were able to compare clinical characteristics of patients with both COVID-19 and cerebrovascular disease (n=113) and those without cerebrovascular disease (n=11,683). Patients with COVID-19 who also had cerebrovascular risk factors such as hypertension, diabetes mellitus, and coronary artery disease demonstrated increased risk for stroke. The patients were also older and there were no differences in male versus female. Interestingly, their research did not demonstrate any significant difference between smokers and non-smokers.¹⁹

In their meta-analysis of clinical characteristics of patients with both COVID-19 and acute cerebrovascular disease, the above authors ¹⁹ examined fifty studies. The

authors found that median age was 65.3 years with the majority being male.

Hypertension, diabetes mellitus, and dyslipidemia were the most common vascular risk factors. Severe COVID-19 was seen in 61% of the patients with 86.7% demonstrating radiologic evidence of pneumonia and 14.8% of patients were afflicted with pulmonary embolism.¹⁹

Clinical implications for the above study¹⁹ include:

- Incidence of stroke could complicate the course of COVID-19 with those older and having more severe infection presenting a higher risk
- Though incidence of stroke in COVID-19 population was less than 2%, this would have a global impact because of sheer numbers of people infected by the virus
- Clinicians, including nurses, should be vigilant in their bedside assessments observing for acute neurologic symptom development in patients with COVID-19
- Patients who are intubated and/or sedated require close monitoring incorporating assessment of pupillary reactivity and utilization of the Glasgow Coma Scale which might render discovery of abnormal neurologic manifestations
- Patients who have abnormal coagulation studies or other thrombotic complications deserve close observation for development of sudden abnormal neurologic dysfunction
- Providers should follow a protected stroke pathway for patients with stroke presentation who also have suspected or confirmed COVID-19 infection.


Another study by Qureshi and peers found that in patients with COVID-19, the proportion of patients with hypertension, diabetes mellitus, hyperlipidemia, atrial fibrillation, and congestive heart failure was significantly higher among those with acute ischemic stroke.²¹

Xu and colleagues³⁴ in 2021 found some similarities in risk factor prevalence, specifically with hypertension, hyperlipidemia, diabetes mellitus, atrial fibrillation, and heart failure, in their study as outlined below:

Figure 1. Vascular Risk Factor Prevalence in Patients³⁴

- Hypertension
- Hyperlipidemia
- Former/Current smoker
- Diabetes Mellitus
- Atrial fibrillation
- Chronic Kidney Disease
- Coronary Artery Disease
- Heart Failure
- Obesity
- Cancer
- Deep Vein Thrombosis

Highest



- Pulmonary Embolus
 - Sleep Apnea
 - Prior stroke
- Lowest

In an international multicenter retrospective study including 50 comprehensive stroke centers with a cohort of 575 patients with large vessel occlusion, Jabbour and colleagues²⁵ found that 194 of the patients were positive for COVID-19.

The group members were younger (62.5 years), had fewer risk factors for cerebrovascular disease, and experienced higher morbidity and mortality rates.

MECHANISMS OF HYPERCOAGULABILITY IN COVID-19

The specific process through which COVID-19 lends to a hypercoagulable state in the infected population is unknown but understanding the pathophysiology of the hypercoagulable state is key to optimizing treatment to those with COVID-19 induced ischemic stroke and for the prevention of ischemic stroke in those with COVID-19 infection. Inflammation and hypercoagulability are influenced by a cytokine storm which interacts with the coagulation cascade. Studies show cytokines cause neutrophil extracellular traps (NETs) which turn on the extrinsic and intrinsic coagulation pathways creating thrombin which promote coagulation and lead to acute ischemic stroke.³⁵

COVID-19 invades endothelial cells in vessels, tissues, and organs through the angiotensin-converting enzyme 2 (ACE 2) which can damage renal, intestine and lung tissue. It is known fact that damaged endothelial cells are related to ischemic stroke. Interestingly, cerebral neurons and vascular smooth muscle cells have the ACE 2

receptor which allow the virus to cross the blood brain barrier creating central nervous system damage and promote central thrombosis.³⁵

Patients with severe cases of COVID-19 have low platelet and lymphocyte counts and increased neutrophils, D-dimer and C-reactive protein levels. It has been hypothesized the virus interferes with lymphocytes by decreasing platelet production, increasing platelet destruction, and then possibly to thrombosis leading to platelet consumption. Platelet activation related to a hypercoagulable state in patients with COVID-19 may increase the risk of acute ischemic stroke.³⁵

During the inflammatory cascade, neutrophils utilize neutrophil extracellular traps (NETs) to capture bacteria. These NETs are made from DNA and proteins which are possibly related to diseases in a hypercoagulable state promoting thrombosis which in turn may contribute to acute ischemic stroke.³⁵

Activated platelet release particles (MPs) result from apoptosis of cells. They are the result from various cells such as erythrocytes, platelets, and endothelial cells. MPs are suspected to cause hypercoagulability in many disease states including stroke.³⁵

The immune system utilizes the complement system for protection against viruses. Lack of an adequately functional complement system can cause a system wide inflammatory response creating tissue damage. Coagulation and micro-thrombosis are also associated with the activation of the complement system.³⁵

Patients who become hypoxic from the development of acute respiratory distress syndrome with severe COVID-19 infection trigger pathways leading to thrombosis. It is suspected that bacteria or viruses promote antiphospholipid antibodies thereby patients

with COVID-19 promoting antiphospholipid production are at risk for hypercoagulability state induced ischemic stroke.³⁵

MBonde and colleagues (2022), proposed that the pathophysiology of AIS with

COVID-19 involves:

- Inflammatory response
- Coagulopathy
- Endothelial dysfunction
- Platelet activation
- Cardioembolic phenomenon

IMPLICATIONS FOR FUTURE RESEARCH

COVID-19 vaccination status is one cohort for new researchers to consider when collecting data and looking at the relationship between COVID-19 and stroke risk.

Kakovan and associates indicate that vaccine-induced thrombotic thrombocytopenia or VITT may be associated with stroke post COVID-19 vaccine.³⁶ Clinicians should be

aware of possible stroke after COVID-19 vaccination to ensure rapid diagnosis and treatment. Should a patient develop any new neurological symptoms, especially

constant headaches, within a month of receiving a COVID-19 vaccine, moderate

suspicion for stroke should be considered. Laboratory testing for possible VITT could

include platelet count, D-dimer, anti-PF4 antibody, fibrinogen level, and brain imaging.

Additionally, those with VITT should be evaluated for concurrent thrombotic diagnoses

such as deep vein thrombosis, pulmonary thromboembolism, and venous thrombosis.³⁶

Stroke and cerebral venous thrombosis have been reported in the Vaccine Adverse Event Reporting System (VAERS) specific to the Pfizer-BioNTech, Moderna, and J&J/Janssen COVID-19 vaccines.¹⁶ Though there is not yet a plethora of data supporting this, consideration of COVID-19 vaccine status is not unreasonable.

Huth and colleagues¹⁵ concluded that more robust studies using standardized screening and case definitions are warranted. This was certainly apparent with our literature review and review of studies.

In their retrospective study (n = 368), Oates and associates³⁷ found support for the use of transthoracic echocardiography (TTE) in patients with COVID-19 to assist in risk detection of ischemic stroke. The authors developed a composite risk score using clinical and echocardiographic characteristics:

- Age less than 55 years
- Systolic blood pressure greater than 140 mm Hg
- Anticoagulation prior to admission
- Left atrial dilation
- Left ventricular thrombus

The researchers³⁷ found increased incidence of left atrial dilation and left ventricular thrombus (48.3% vs 27.9%, $p = 0.04$; 4.2% vs 0.7%, $p = 0.03$) in patients with ischemic stroke. TTE is currently utilized as a part of the diagnostic workup for stroke and TIA. This non-invasive diagnostic test could be utilized more in those with severe COVID-19 with suspected stroke.³⁷

CLINICS CARE POINTS

- Worldwide research examining comparisons of COVID-19 positive and COVID-19 negative stroke cohorts demonstrate a relationship between COVID-19 and ischemic stroke.
- Providers must address control of risk factors such as hypertension, high coagulability states, and diabetes mellitus in patients with COVID-19.
- Public health campaigns focusing on stroke recognition and emphasizing the need to seek care for stroke, even during a pandemic, are needed.
- COVID-19 best practice guidelines should be incorporated within the American Heart Association/American Stroke Association Stroke guidelines.
- COVID-19 associated stroke can affect the young, with or without cerebrovascular risk factors.
- Morbidity and mortality are much worse in patients with COVID-19 and stroke as compared to patients with only stroke
- Hypercoagulability studies should be considered and completed on younger patients with stroke, with or without COVID-19 symptoms
- On patients with suspected stroke, a full stroke workup is warranted, even if done post-discharge through an outpatient setting
- More robust research is needed for the prevention and treatment of COVID-19

CLINICAL RELEVANCE

In summary, there are many elements which participate in the activation of the immune system in patients infected with COVID-19 leading to a hypercoagulable state beginning with the trigger of a cytokine storm which creates subsequent endothelial cell damage and the production of NETs, distribution of MPs, platelet activation, and the

initiation of the complement system. It is also important to understand hypoxia is a causal factor in COVID-19 related stroke. The cerebrum is sensitive to changes in oxygenation, so hypoxia can not only cause interstitial cerebral edema but also initiate the coagulation cascade ³⁵.

Antithrombotic therapy targeting the various mechanisms which lead to thrombosis should be considered in COVID-19 infected patients. Antithrombotic therapy increases oxygen saturation levels in the blood and the coagulopathy. Complications of COVID-19 lead to increased risk for acute ischemic stroke. Therefore, anticoagulation should be initiated early during the initial phase of COVID-19 to prevent acute ischemic stroke.³⁵

Since the pandemic, studies have alluded to stroke patients with COVID-19 being younger and having a higher initial admission National Institutes of Health Stroke Scale (NIHSS) than those without COVID-19 infection. Laboratory data to assess for hypercoagulation or inflammation such as d-dimer, interleukin-6, C-reactive protein, fibrinogen, and platelets are usually elevated in the COVID-19 patient. All efforts should be made to adhere to national guidelines of stroke care.³⁹

The COVID-19 pandemic created a greater opportunity for telemedicine. Utilization of telemedicine enabled social distancing and the ability to maintain isolation between patients and providers. Tele-Neurology is available to allow vascular neurologist to oversee stroke activations in remote facilities or where expertise is unavailable. It also provides quick use of the NIHSS to provide assessment from symptom onset to treatment and management more efficiently.³⁹

Patient evaluation for symptoms of ischemic stroke should result in a full stroke workup. Typically, an initial neurologic evaluation is performed to assess deficits followed by cerebral and vascular imaging is performed. A cardiac work up and coagulation panel are included. Results of the imaging and patient eligibility as per stroke guidelines^{3,4} determine interventions of intravenous thrombolytic or mechanical thrombectomy.³⁹

Clinicians may assume stroke symptoms typically occur in the elderly population, but what we have seen since the COVID-19 pandemic are younger people including children experiencing stroke symptoms.^{39, 40} Stroke in the young usually include further work up to explain their hypercoagulable state or cause for stroke. It is important for nursing to utilize a standardized tool such as the NIHSS to monitor for subtle neurologic changes in patients which may not be otherwise explained and advocating for neuroimaging. A standardized inpatient stroke code protocol should be implemented and familiar. As clinicians, identifying patient risk factors for stroke and being able to identify neurological changes early and knowing the time when the patient was last known normal are essential for timely stroke intervention.⁴¹

SUMMARY

In January 2022, for the 20th year in a row, nurses were ranked number one as the most trusted profession⁴² despite the pandemic and its related critical staffing and equipment shortages, threat to their personal safety and that of their patients, co-workers, and families, and extreme physical and mental duress. Data and quality of care have long been linked to promote optimum patient outcomes. Accuracy of that data is crucial. Since nurses are the largest group of healthcare professionals and play a key

role in patient safety and quality outcomes, it is imperative that they have access to quality, robust data and be knowledgeable about its interpretation so that they can make informed practice decisions.⁴³

Three years into the COVID-19 pandemic, there is growing evidence that the increased incidence of vascular risk factors with concomitant proinflammatory and procoagulation biomarkers demonstrate a distinct relationship of ischemic stroke risk in patients with SARS-CoV-2 infection.⁷ Despite governmental assurances that the pandemic is over, long-term effects of COVID-19 continue to evolve. Other than vaccination, academic literature is still lacking with respect to prevention and early treatment of COVID-19 as well its long-term effects.

Declarations of interest: The authors have nothing to disclose.

REFERENCES

1. Katsanos AH, Palaiodimou L, Zand R, et al. The Impact of SARS-CoV-2 on Stroke Epidemiology and Care: A Meta-Analysis. *Ann Neurol*. 2021;89(2):380-388. doi:10.1002/ana.25967
2. Finsterer, Josef, Scorza FA, Scorza CA, Fiorini AC. Ischemic stroke in 455 COVID-19 patients. *Clinics*, Volume 77, 2022, <https://doi.org/10.1016/j.clinsp.2022.100012>.
3. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals

From the American Heart Association/American Stroke Association [published correction appears in *Stroke*. 2019 Dec;50(12):e440-e441]. *Stroke*. 2019;50(12):e344-e418. doi:10.1161/STR.0000000000000211

4. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in *Stroke*. 2015 Feb;46(2):e54]. *Stroke*. 2014;45(7):2160-2236. doi:10.1161/STR.0000000000000024

5. Schlachetzki F, Theek C, Hubert ND, Kilic M, Haberl RL, Linker RA, & Hubert JJ (2020). Low stroke incidence in the TEMPiS telestroke network during COVID-19 pandemic: Effect of lockdown on thrombolysis and thrombectomy. *Journal of Telemedicine and Telecare*, 28(7), 481-487. <https://doi.org/10.1177/1357633X20943327>

6. World Health Organization. (2022, July 10). *Coronavirus disease (COVID-19) pandemic*. World health organization. Retrieved August 7, 2022, from <https://www.who.int/emergencies/disease/novel-coronavirus-2019>

7. Zhang Y, Xiao M, Zhang S, Xia P, Cao, W, Jiang W, Chen H., Ding X, Zhao H., & Zhang H. (2020). Coagulopathy and Antiphospholipid Antibodies in Patients with COVID-19. *The New England Journal of Medicine*, 382(38), 1. <https://doi.org/10.1056/NEJMc2007575>

8. Belani, P, Schefflein J, Kihira S, Rigney B, Delman BN, Mahmoudi K., Mocco, J, Majidi S, Yechley J, Aggarwal A, Lefton D, & Doshi AH (2020). COVID-19 Is an

Independent Risk Factor for Acute Ischemic Stroke. *American Journal of Neuroradiology*, 41(8), 1361-1364. <https://doi.org/10.3174/ajnr.A6650>

9. Mbonde AA, O'Carroll CB, Grill MF, Zhang N, Butterfield R, Demaerschalk BM. Stroke Features, Risk Factors, and Pathophysiology in SARS-CoV-2-Infected Patients. *Mayo Clin Proc Innov Qual Outcomes*. 2022;6(2):156-165.
doi:10.1016/j.mayocpiqo.2022.01.003

10. Mao L, Jin H, Wang M. Neurologic manifestations of hospitalized patients with Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurology* vol.77, 6 (2020); 683-90.
doi: 10.1001/jamaneurol.2020.1127. Published online April 10, 2020.

11. Maury A, Lyoubi A, Peiffer-Smadja N, de Broucker T, Meppiel E. Neurological manifestations associated with SARS-CoV-2 and other coronaviruses: A narrative review for clinicians. *Rev Neurol (Paris)*. 2021;177(1-2):51-64.
doi:10.1016/j.neurol.2020.10.001

12. Taquet, M, Geddes J, Husain M, et al. 6-month neurological and psychiatric outcomes in 236379 survivors of COVID-19: a retrospective cohort study using electronic health records, *Lancet Psychiatry* 2021; 8: 416–2.

13. Li Y, Li M, Wang M, Zhou, Y. Acute cerebrovascular disease following COVID-19: A single center, retrospective, observational study. *Stroke Vasc Neurol*. 2020;5(3):279–84.

14. Shahjouei S, Naderi S, Li J, et al. Risk of stroke in hospitalized SARS-CoV-2 infected patients: A multinational study. *EBioMedicine*. 2020;59:102939.
doi:10.1016/j.ebiom.2020.102939

15. Huth SF, Cho SM, Robba C, et al. Neurological Manifestations of Coronavirus Disease 2019: A Comprehensive Review and Meta-Analysis of the First 6 Months of Pandemic Reporting. *Front Neurol.* 2021;12:664599. Published 2021 Aug 12.
doi:10.3389/fneur.2021.664599
16. Srivastava PK, Zhang S, Xian Y, et al. Acute Ischemic Stroke in Patients With COVID-19: An Analysis from Get With The Guidelines-Stroke. *Stroke.* 2021;52(5):1826-1829. doi:10.1161/STROKEAHA.121.034301
17. Mahammedi A, Saba L, Vagal A, et al. Imaging of Neurologic Disease in Hospitalized Patients with COVID-19: An Italian Multicenter Retrospective Observational Study. *Radiology.* 2020;297(2):E270-E273.
doi:10.1148/radiol.2020201933
18. Romero-Sánchez CM., Díaz-Maroto I, Fernández-Díaz E. Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry. *Neurology.* 2020;95(8) doi: 10.1212/WNL.0000000000009937. e1060-e1070
19. Nannoni S, de Groot R, Bell S, Markus HS. Stroke in COVID-19: A systematic review and meta-analysis. *Int J Stroke.* 2021;16(2):137-149.
doi:10.1177/1747493020972922
20. Shakil SS, Emmons-Bell S, Rutan C, et al. Stroke Among Patients Hospitalized With COVID-19: Results from the American Heart Association COVID-19 Cardiovascular Disease Registry. *Stroke.* 2022;53(3):800-807. doi:10.1161/STROKEAHA.121.035270

21. Qureshi AI, Baskett WI, Huang W, et al. Acute Ischemic Stroke and COVID-19: An Analysis of 27 676 Patients. *Stroke*. 2021;52(3):905-912.
doi:10.1161/STROKEAHA.120.031786
22. Siegler JE, Cardona P, Arenillas JF, et al. Cerebrovascular events and outcomes in hospitalized patients with COVID-19: The SVIN COVID-19 Multinational Registry. *Int J Stroke*. 2021;16(4):437-447. doi:10.1177/1747493020959216
23. Román GC, Spencer PS, Reis J, et al. The neurology of COVID-19 revisited: A proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries. *J Neurol Sci*. 2020;414:116884. doi:10.1016/j.jns.2020.116884
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204734/>
24. Shahjouei S, Tsivgoulis G, Farahmand G, et al. SARS-CoV-2 and Stroke Characteristics: A Report from the Multinational COVID-19 Stroke Study Group. *Stroke*. 2021;52(5):e117-e130. doi:10.1161/STROKEAHA.120.032927
25. Jabbour P, Dmytriw AA, Sweid A, et al. Characteristics of a COVID-19 Cohort With Large Vessel Occlusion: A Multicenter International Study. *Neurosurgery*. 2022;90(6):725-733. doi:10.1227/neu.0000000000001902
26. Yang Q, Tong X, George MG, Chang A, Merritt RK. COVID-19 and Risk of Acute Ischemic Stroke Among Medicare Beneficiaries Aged 65 Years or Older: Self-Controlled Case Series Study. *Neurology*. 2022;98(8):e778-e789.
doi:10.1212/WNL.00000000000013184

27. Shahjouei S, Tsivgoulis G, Farahmand G, et al. SARS-CoV-2 and Stroke Characteristics: A Report from the Multinational COVID-19 Stroke Study Group. *Stroke*. 2021;52(5):e117-e130. doi:10.1161/STROKEAHA.120.032927
28. Stein, L K, Mayman, N A, Dhamoon, M S, Fifi, J T, The emerging association between COVID-19 and acute stroke, *Trends in Neurosciences*, Volume 44, Issue 7, 2021, Pages 527-537, <https://doi.org/10.1016/j.tins.2021.03.005>.
29. Siegler JE, Cardona P, Arenillas JF, et al. Cerebrovascular events and outcomes in hospitalized patients with COVID-19: The SVIN COVID-19 Multinational Registry. *Int J Stroke*. 2021;16(4):437-447. doi:10.1177/1747493020959216
30. Lee KW, Yusof Khan AHK, Ching SM, Chia PK, Loh WC, Abdul Rashid AM, et al.. Stroke and novel coronavirus infection in humans: a systematic review and meta-analysis. *Front Neurol*. (2020) 11:1196. 10.3389/fneur.2020.579070
31. John S, Kesav P, Mifsud VA, Piechowski-Jozwiak B, Dibu J, Bayrlee A, et al. Characteristics of large-vessel occlusion associated with COVID-19 and ischemic stroke. *Am J Neuroradiol*. (2020) 41:2263–8. 10.3174/ajnr.A6799
32. Shahjouei S, Anyaehie M, Koza E, et al. SARS-CoV-2 Is a Culprit for Some, but Not All Acute Ischemic Strokes: A Report from the Multinational COVID-19 Stroke Study Group. *J Clin Med*. 2021;10(5):931. Published 2021 Mar 1. doi:10.3390/jcm10050931
33. Ntaios, George, et al. "Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke: The Global COVID-19 Stroke Registry." *Stroke* (00392499), vol. 51, no. 9, Sept. 2020, pp. e254–58. EBSCOhost, <https://doi.org.ezproxy.nicholls.edu/10.1161/STROKEAHA.120.031208>.

34. Xu Y, Zhuang Y, Kang L. A Review of Neurological Involvement in Patients with SARS-CoV-2 Infection. *Med Sci Monit.* 2021;27:e932962. Published 2021 Jun 19. doi:10.12659/MSM.932962
35. Abou-Ismaïl MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. *Thrombosis Research.* 2020 Oct;194:101-115. doi: 10.1016/j.thromres.2020.06.029
36. Kakovan M, Ghorbani Shirkouhi S, Zarei M, Andalib S. Stroke Associated with COVID-19 Vaccines. *J Stroke Cerebrovasc Dis.* 2022;31(6):106440. doi:10.1016/j.jstrokecerebrovasdis.2022.106440
37. Oates, Connor P., et al. "Using Clinical and Echocardiographic Characteristics to Characterize the Risk of Ischemic Stroke in Patients with COVID-19." *Journal of Stroke & Cerebrovascular Diseases*, vol. 31, no. 2, Feb. 2022, p. N.PAG. EBSCOhost, <https://doi-org.ezproxy.nicholls.edu/10.1016/j.jstrokecerebrovasdis.2021.106217>.
39. Qi X, Keith KA, Huang JH. COVID-19 and stroke: A review. *Brain Hemorrhages.* 2021 Jun;2(2):76-83. doi: 10.1016/j.heest.2020.11.001. Epub 2020 Nov 17. PMID: 33225251; PMCID: PMC7670261.
39. Appavu, Brian, et al. Arteritis and Large Vessel Occlusive Strokes in Children After COVID-19 Infection. *Pediatrics*, vol. 147, no. 3, Mar. 2021, pp. 1–7. EBSCOhost, <https://doi-org.ezproxy.nicholls.edu/10.1542/peds.2020-023440>.
40. Coronado Munoz, A, Tasayco, J, Morales, W et al. High incidence of stroke and mortality in pediatric critical care patients with COVID-19 in Peru. *Pediatr Res* 91, 1730–1734 (2022). <https://doi.org/10.1038/s41390-021-01547-x>

41. Assuncao, C., Evers, B., Martins, C., Remmel, K., Comparison of Code Stroke Response Times Between Emergency Department and Inpatient Settings in a Primary Stroke Center. *Journal of Neurology Research*, North American, 11, August 2021. <https://www.neurores.org/index.php/neurores/article/view/6888/658>.
42. Saad, L. "Military Brass, Judges Among Professions at New Image Lows". January 12, 2022. Retrieved from <https://news.gallup.com/poll/388649/military-brass-judges-among-professions-new-image-lows.aspx>
43. Glasman, KS. "Using data in nursing practice" (2017). Retrieved from <https://www.myamericannurse.com/wp-content/uploads/2017/11/ant11-Data-1030.pdf>